BROMHEXINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H20Br2N2
Molecular Weight	376.13
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(CC1=C(N)C(Br)=CC(Br)=C1)C2CCCCC2

InChI

InChIKey=OJGDCBLYJGHCIH-UHFFFAOYSA-N

InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3

HIDE SMILES / InChI

Molecular Formula	C14H20Br2N2
Molecular Weight	376.13
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.hpra.ie/img/uploaded/swedocuments/2173773.PA0007_025_002.aa7cc0c2-c2ff-4b55-80c9-8e666ce5f551.000001Product%20Leaflet%20Approved.160429.pdf
Curator's Comment: description was created based on several sources, including: http://www.drugsupdate.com/generic/view/745/Bromhexine | https://www.old.health.gov.il/units/pharmacy/trufot/alonim/5329.pdf | https://docetp.mpa.se/LMF/Bisolvon%20oral%20solution%20in%20sachet%20ENG%20PAR.pdf

Bromhexine is used for conditions where there are a lot of thick mucus in the airways. Bromhexine acts on the mucus at the formative stages in the glands, within the mucus-secreting cells. Bromhexine disrupts the structure of acid mucopolysaccharide fibres in mucoid sputum and produces a less viscous mucus, which is easier to expectorate. In addition, bromhexine has antioxidant properties. Occasional, mild side effects include: a feeling of fullness in the stomach (bloatedness), diarrhea, dizziness, headache, indigestion, nausea, sweating and skin rashes. Bromhexine may increase the concentration of concurrently administered antibiotics in bronchial secretions. No clinically relevant interactions with other medications have been reported.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
mucopolysaccharide metabolic process 2 Target ID: GO:1903510 Sources: http://www.drugsupdate.com/generic/view/745/Bromhexine	Modulator 822
response to oxidative stress 20 Target ID: GO:0006979 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8831801	Modulator 822

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bronchopulmonary diseases 2 Sources: http://www.hsa.gov.sg/content/dam/HSA/HPRG/Western_Medicine/Overview_Framework_Policies/Reclassified_Medicines/Updates/Patient_Information_Leaflets/PIL_Bromhexine_29-6-2011.pdf	Palliative		Approved 8360	Bisolvon Approved Use Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.

PubMed

Title	Date	PubMed
Therapy of Sjögren's syndrome. New aspects and future directions.	1998 Feb	11490519
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures.	2001 Apr	11340978
Efficacy and safety of Ascoril in the management of cough--National Study Group report.	2001 Feb	11482804
Determination of ambroxol or bromhexine in pharmaceuticals by capillary isotachophoresis.	2001 Jan	11199221
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
Solubilization of bromhexine hydrochloride in aqueous lecithin dispersions. Physicochemical characterization of interactions between drug and carrier.	2001 Sep	11593995
Stevens-Johnson syndrome presumably induced by bromhexine. A case report.	2002 Apr	11965223
[Use of mucoregulating drugs in combined therapy of exudative otitis media].	2003	12958859
[Treatment of patients with acute pneumonia].	2003 Apr-Jun	12889364
In vitro inhibition of human neutrophil histotoxicity by ambroxol: evidence for a multistep mechanism.	2003 Oct	14534155
Metabolism of bromhexine in pig hepatocyte cultures.	2004 Aug	15305850
Mediastinal pancreatic pseudocyst caused by obstruction of the pancreatic duct was eliminated by bromhexine hydrochloride.	2004 Nov	15609697
Congenital chylothorax associated with isolated congenital hypoplastic superior caval vein: a case report.	2005 Dec	16421051
Gastrointestinal stromal tumor in a child and review of the literature.	2005 Nov	16240136
Progress and regression within primary Sjögren's syndrome.	2006 Jan-Feb	16467033
[Abdominal tuberculosis in CT imaging].	2007	17650598
Mediastinal extension of a complicated pancreatic pseudocyst; a case report and literature review.	2007 Apr 25	17459155
[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Recommendations for supportive therapy for Sjögren's syndrome].	2007 Feb	17221252
Amiodarone inhibits tocopherol-mediated human lipoprotein peroxidation.	2007 Jul 15	17531203
Hemorrhage into pancreatic pseudocyst.	2007 May-Jun	16944033
Acute cholecystitis due to strangulation of a floating gallbladder by the lesser omentum.	2007 May-Jun	16897276
The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.	2008	19281081
Subjective pulsatile tinnitus associated with extensive pneumatization of temporal bone.	2008 Jan	17647005
Chemiluminescence determination of bromhexine hydrochloride with morin as chemiluminescent reagent.	2008 Jan-Feb	18175361
Development and evaluation of oral controlled release chlorpheniramine-ion exchange resinate suspension.	2008 Jul-Aug	20046790
Three case reports of laparoscopic management of granulosa cell tumor with intraoperative rupture and subsequent upstaging.	2008 Jul-Aug	18602055
Malignant medulloepithelioma of optic nerve head.	2008 Jun	18525470
The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma.	2008 Mar	17657202
Mediastinal pancreatic pseudocyst with isolated thoracic symptoms: a case report.	2008 May 27	18505589
[Traumatic perforation of the duodenum--a case review].	2009 Feb	19413259
Simultaneous determination of salbutamol sulphate and bromhexine hydrochloride in tablets by reverse phase liquid chromatography.	2009 Jan	20177457
Feline calicivirus infection. ABCD guidelines on prevention and management.	2009 Jul	19481035
Molecularly imprinted solid-phase extraction for the selective determination of bromhexine in human serum and urine with high performance liquid chromatography.	2009 Nov 15	19782202
Differential modulation of IgE-dependent activation of human basophils by ambroxol and related secretolytic analogues.	2009 Oct-Dec	20074455
Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases.	2010 Apr	20616932
Analyses and localization of pectin-like carbohydrates in cell wall and mucilage of the green alga Netrium digitus.	2010 Jul	19340523
[Codeine and cutaneous drug reactions: Absence of cross-allergy with tramadol and fentanyl].	2010 May	20470933
Superior mesenteric artery aneurysm: importance of sonography as the primary imaging technique for detection.	2010 Oct	20876907
Contaminations of herbal products determined by NMR fingerprint.	2010 Sep	20803376

Patents

Sample Use Guides

In Vivo Use Guide

8 to 16 mg three times daily

Route of Administration: Oral

In Vitro Use Guide

Bromhexine is shown to be scavengers of both superoxide and hydroxyl radicals. The dismutation of superoxide was accelerated 3-fold by bromhexine over the rate of spontaneous dismutation. The reaction constant of hydroxyl radicals with bromhexine was determined by competition kinetics to be 1.58 +/- 0.15 x 10(10) M-1S-1.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:51:27 UTC 2023` Edited by `admin` on `Wed Jul 05 22:51:27 UTC 2023`
Record UNII	Q1J152VB1P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BROMHEXINE

Official Name

English

BROMHEXINE [MI]

Common Name

English

BROMHEXINE [MART.]

Common Name

English

bromhexine [INN]

Common Name

English

Bromhexine [WHO-DD]

Common Name

English

BENZENEMETHANAMINE, 2-AMINO-3,5-DIBROMO-N-CYCLOHEXYL-N-METHYL-

Systematic Name

English

FLUIBRON

Brand Name

English

Classification Tree Code System Code

WHO-ATC

R05CB02